GLP-1 Agonists Are Quietly Reducing Addiction Hospitalizations, But Only While Patients Take Them
A Lancet Psychiatry study shows GLP-1 agonists cut AUD and SUD hospitalizations, but the protection fades after stopping —...
Glofitamab Plus Englumafusp Alfa: When Phase 1 Data Rewrites the Combination Therapy Playbook
A Nature Medicine phase 1 trial pairs glofitamab with CD19-4-1BBL co-stimulation in r/r B-NHL, producing efficacy signals that challenge...
Roche’s Englumafusp Plus Glofitamab Combination Shows Why Phase 1 Trial Design Is the Real Competitive Moat in Bispecific Oncology
A Nature Medicine Phase 1 trial combining englumafusp alfa and glofitamab in B-cell NHL reveals how rational dose escalation...
The Bispecific Combination Wave Is Here: What the Englumafusp-Glofitamab Trial Signals for Hematology Trial Design
A Phase 1 trial pairing englumafusp alfa with glofitamab in B-cell NHL reveals a mechanistic shift reshaping how sponsors...
SCI-110’s Phase IIb in Tourette Syndrome: What Hannover Tells Us About Cannabinoid Trial Design in CNS
NeuroThera Labs activates Hannover Medical School for SCI-110 Phase IIb in adult Tourette Syndrome, building on a 21% tic...
The Trial You Never Have to Run: How Simulation Is Rewriting Clinical Development Economics
Nature Reviews Drug Discovery's 2026 simulation-guided trial framework shows sponsors how digital modeling can cut sample sizes 13–23% and...
Checkpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.
A 46-patient LAG-3/PD-1 phase 1 trial in recurrent GBM reveals the protocol innovations sponsors need before scaling immunotherapy in...
FDA’s Single-Trial Default: What It Actually Means for Your Protocol Strategy
FDA made a single pivotal trial its default approval standard on Feb. 19, 2026. Here's what clinical ops leaders...
The Serotonin Signal Hiding in Plain Sight Across Two Rapid-Acting Depression Treatments
A Bayesian PET re-analysis finds ketamine and ECT both upregulate 5-HT1B receptors, pointing to a shared biomarker that TRD...
The Trial Without Walls: How Real-World Evidence Is Rewriting the Rules of Drug Approval
Nature Medicine's RWE trial emulation framework is reshaping FDA approval pathways. Here's what sponsors running traditional RCTs need to...